VioQuest to file NDA for parasitic disease treatment, VQD-001

By Lisa Kerner

Charlotte, N.C., June 12 - VioQuest Pharmaceuticals, Inc. said it plans to submit a New Drug Application in 2007 to the Food and Drug Administration for VQD-001 (sodium stibogluconate), a protein tyrosine phosphatase inhibitor, for the treatment of the parasitic disease leishmaniasis.

The company met with the FDA to discuss the filing, which will be based upon published studies and data compiled by the U.S. Army, which has been administering sodium stibogluconate to treat leishmaniasis in servicemen and women serving in Iraq.

VioQuest is a Basking Ridge, N.J., biopharmaceutical company developing therapies with unique mechanisms of action for oncology, viral and autoimmune disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.